NCCN Guidelines Version 5.2022
- Active (symptomatic) Myeloma
- Multiple Myeloma
- Smoldering (asymptomatic) Myeloma
- Solitary Plasmacytoma
Multiple Myeloma-English Version 2022
Multiple Myeloma-Korean Version 2022
Multiple Myeloma-Russian Version 2019
Continuing Education
NCCN Guidelines® Insights - Multiple Myeloma, Version 3.2022
Newly Diagnosed Multiple Myeloma: How Many Drugs are Enough?
Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma
Toxicities of CAR T-Cell Therapy: Beyond CRS and Neurotoxicity
Recorded Presentation from the NCCN Pharmacy Updates: CAR-T Therapy in Multiple Myeloma
Translations
Arabic Version 3.2022
Chinese Version 3.2022
French Version 3.2022
German Version 3.2022
Italian Version 3.2022
Japanese Version 3.2022
Korean Version 3.2022
Portuguese (Latin America) Version 3.2022
Russian Version 3.2022
Spanish (European Editions) Version 3.2022
Spanish (Latin America) Version 5.2022
Adaptations
Portuguese (Latin America) Version 3.2017
Harmonized
English (Caribbean) Version 4.2018
English (Africa) Version 4.2021